CD33 and myeloid neoplasm: Even before the development of imatinib, the targeting of myeloid surface markers yielded the first precision drug in myeloid malignancies in 2000: the anti-CD33 antibody–drug conjugate (ADC) gemtuzumab ozogamicin (GO).